Asset
Indication
Preclinical
Phase I
Phase 2A
Phase 2B
Phase 3
Status
Resomelagon
(AP1189)
Rheumatoid arthritis (RA)
- 1st line treatment together Methotrexate
• ADVANCE Ph2b
study ongoing
Host-Directed Therapy in Viral Infections
• RESOVIR-2 - Ph2a study in Dengue Fever ongoing
Idiopathic Membranous
Nephropathy (iMN)
• Ph2a study onging
TXP-11
Prevent organ
failure in surgery
• Preclinical pharmacology
to support Ph-1 CTA
ongoing - aim to be
Ph-1 ready in 2025
Next generation
molecules
Autoimmune &
inflammatory diseases
• Discovery phase
Polymyalgia Rheumatica (PMR)
• Phase IIa study to be initiated
Completed Ongoing